GlassScriptPhysician profile
Sandra M Goldberg
NPI 1922259316
$6,147.67
in general payments reported to CMS, 2019-2025
26 companies · $1,355 in 2025
The $1,355 reported for 2025 was more than what 85% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $436 · 2022: $1,174 · 2023: $1,283 · 2024: $1,899 · 2025: $1,355.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,829 · Travel and Lodging: $449 · Education: $259.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,829.49 |
| Travel and Lodging | $449.21 |
| Education | $258.64 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $790.26 | 2023-2025 | Varithena Administration Pack |
| Incyte Corporation | $711.81 | 2022-2025 | Opzelura |
| Abbvie INC. | $509.58 | 2021-2025 | |
| Genzyme Corporation | $491.20 | 2022-2025 | |
| Amgen INC. | $481.82 | 2021-2025 | Otezla, Otezla |
| Ucb, INC. | $411.67 | 2021-2025 | Bimzelx, Cimzia |
| Sun Pharmaceutical Industries INC. | $400.46 | 2021-2025 | Ilumya |
| Janssen Biotech, INC. | $394.96 | 2022-2025 | Tremfya |
| Regeneron Healthcare Solutions, INC. | $328.01 | 2023-2025 | Dupixent |
| Janssen Scientific Affairs, LLC | $267.26 | 2022 | |
| Angiodynamics, INC. | $195.35 | 2021-2025 | Venacure 1470 Pro |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $188.92 | 2022-2025 | Cabtreo, Jublia, Arazlo |
| Pfizer INC. | $169.78 | 2021-2023 | |
| Leo Pharma INC. | $160.87 | 2022-2025 | Anzupgo, Adbry |
| Lnhc, INC | $107.13 | 2025 | Zelsuvmi |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Galderma Laboratories, L.P. | $95.44 | 2022-2025 | Aklief, Oracea |
| Almirall LLC | $92.41 | 2022-2025 | Seysara, Klisyri |
| Arcutis Biotherapeutics, INC. | $86.84 | 2023-2024 | Zoryve |
| Novartis Pharmaceuticals Corporation | $73.96 | 2023-2025 | |
| Bausch Health US, LLC | $45.00 | 2021 | |
| Dermavant Sciences, INC. | $32.46 | 2023-2024 | Vtama |
| Pierre Fabre Pharmaceuticals, INC. | $29.48 | 2021 | |
| Organon LLC | $25.46 | 2025 | Vtama |
| Organogenesis INC. | $24.57 | 2025 | Via Matrix |
| Verrica Pharmaceuticals INC. | $18.50 | 2024 | Ycanth |
| Botanix Sb INC | $14.47 | 2025 | Sofdra |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sandra Goldberg listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.